MedPath

Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.

Phase 4
Terminated
Conditions
Post Operative Analgesia
Interventions
Registration Number
NCT01882530
Lead Sponsor
Rennes University Hospital
Brief Summary

The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia.

The objectives of this study are :

* comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.

* determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.

* evaluating the effects of NOA on postoperative hyperalgesia.

Detailed Description

Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety?

Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds.

The objectives of this study are :

* comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.

* determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.

* evaluating the effects of NOA on postoperative hyperalgesia.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
223
Inclusion Criteria
  • Adults older than 18 years
  • Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain
  • Patients with a written informed consent
  • Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned)
  • Affiliate to a social security system
Exclusion Criteria
  • Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients
  • Absorption of morphine and / or NOA within 24 hours before surgery
  • Absorption of methadone within 48 hours before surgery
  • History of epilepsy
  • Renal insufficiency (creatinin clearance <30 ml / min MDRD)
  • Hepatic insufficiency
  • Severe respiratory insufficiency
  • Pregnancy or breastfeeding women
  • History of seizures
  • Symptomatic urethroprostatic disorders
  • Angle-closure glaucoma
  • Gastrointestinal, cerebrovascular or other evolving bleedings
  • Active peptic ulcer or active gastritis
  • Severe heart failure
  • History of asthma triggered by taking ketoprofen or similar substances
  • Disable adult person under guardianship
  • Use of nitrous oxide during anesthesia protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Group N: NefopamMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group P: ParacetamolParacetamolAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group N: NefopamNefopamAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group K: KetoprofenKetoprofenAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group K: KetoprofenMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group NK: nefopam and ketoprofenKetoprofenAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group NK: nefopam and ketoprofenMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PNK: paracetamol, nefopam and ketoprofenNefopamAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PNK: paracetamol, nefopam and ketoprofenKetoprofenAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PNK: paracetamol, nefopam and ketoprofenMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group P: ParacetamolMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PN: paracetamol and nefopamParacetamolAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Control group C: PlaceboMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PK: paracetamol and ketoprofenParacetamolAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PN: paracetamol and nefopamMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PK: paracetamol and ketoprofenKetoprofenAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PK: paracetamol and ketoprofenMorphineAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PNK: paracetamol, nefopam and ketoprofenParacetamolAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group PN: paracetamol and nefopamNefopamAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Group NK: nefopam and ketoprofenNefopamAll patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Primary Outcome Measures
NameTimeMethod
Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).Day 1
Secondary Outcome Measures
NameTimeMethod
Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.Day 3
Global satisfaction (measured after treatment)Day 3
Morphine consumption (mg) measured by patient controlled analgesia (PCA).Day 2, day 3
Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).Month 3
Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).Day 2

Trial Locations

Locations (19)

Marcel Chauvin

🇫🇷

Boulogne, France

Xavier Capdevila

🇫🇷

Montpellier, France

Hawa Keita-Meyer

🇫🇷

Colombes, France

Dominique Fletcher

🇫🇷

Garches, France

Jacques Ripart

🇫🇷

Nîmes, France

Jean-Xavier Mazoit

🇫🇷

Paris, France

Anissa Belbachir

🇫🇷

Paris, France

Karim Asehnoune

🇫🇷

Nantes, France

Frédéric Aubrun

🇫🇷

Lyon, France

Jean-Marc Malinovsky

🇫🇷

Reims, France

Marc Gentili

🇫🇷

St Grégoire, France

Marc Beaussier

🇫🇷

Paris, France

Hervé Bouaziz

🇫🇷

Nancy, France

Karine Nouette-Gaulain

🇫🇷

Bordeaux, France

Pierre Albaladejo

🇫🇷

Grenoble, France

Marc Raucoules

🇫🇷

Nice, France

Sébastien Bloc

🇫🇷

Quincy sous Sénart, France

Vincent Minville

🇫🇷

Toulouse, France

Emmanuel Marret

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath